Search Results
Your search for ,WHo matches 20376 pages
Showing 10251 - 10300Samuel Waxman, MD, Receives China’s ‘Friendship Award’
The Samuel Waxman Cancer Research Foundation (SWCRF), an international nonprofit organization that funds cancer research, recently announced that its founder and Chief Executive Officer, Samuel Waxman, MD, has received China’s highest honor granted to a foreigner. The Vice-Premier of the People’s...
AR-V7 as Marker for Taxane Therapy in Castration-Resistant Prostate Cancer
In a study reported in JAMA Oncology, Howard I. Scher, MD, of the Genitourinary Oncology Service, Memorial Sloan Kettering Cancer, and colleagues found that the presence of nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells may predict better survival...
Robot-Assisted Laparoscopic Prostatectomy in Newly Diagnosed Prostate Cancer
In an Australian phase III trial reported in The Lancet Oncology, Suzanne K. Chambers, PhD, of the Menzies Health Institute Queensland, Griffith University, Gold Coast, and colleagues found similar functional outcomes at 2 years with robot-assisted laparoscopic prostatectomy and open radical...
Early PSA Testing Could Help Predict Prostate Cancer Among Black Men
In a study published by Mark A. Preston, MD, MPH, and colleagues in European Urology, researchers demonstrated that a baseline prostate-specific antigen (PSA) level obtained from black men between 40 and 60 years old may predict the future development of prostate cancer for years after testing....
Without Genomic Sequencing, I Would Not Be Alive Today
The extreme fatigue I experienced during the winter of my fourth year in medical school, in 2003, was easily attributable to the rigors of my medical training and the lack of sleep that comes from trying to keep up with an intensely busy schedule. I was looking forward to resting and recuperating...
Living a Full Life After a Diagnosis of Cancer
BOOKMARK Title: Here We Grow: Mindfulness Through Cancer and BeyondAuthor: Paige DavisPublisher: She Writes PressDate: May 2018Price: $22.95, paperback, 154 pages Since the publication of Dr. Paul Kalanithi’s best-selling book, When Breath Becomes Air, about his diagnosis of cancer and untimely...
Family Archivist Holds Joyful Memories Amid Grief of Losing Loved Ones
BOOKMARK Title: The Trail to Tincup: Love Stories at Life’s EndEditors: Joyce Lynnette HockerPublisher: She Writes PressPublication date: May 2018Price: $23.95, hardcover, 288 pages Human mortality is embedded in the day-to-day challenges of clinical oncology; a cancer diagnosis is a reality...
Acupuncture for Joint Symptoms Caused by Aromatase Inhibitors
Arthralgia is a common and debilitating adverse effect experienced by patients with breast cancer who are being treated with aromatase inhibitors, often resulting in poor adherence. And premature treatment discontinuation can negatively impact disease-free and overall breast cancer survival....
Nilotinib for Pediatric Patients With Philadelphia Chromosome–Positive CML in Chronic Phase
Earlier in 2018, nilotinib (Tasigna) was approved for the treatment of pediatric patients aged ≥ 1 year with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (CML-CP) or Philadelphia chromosome–positive CML-CP resistant or intolerant to prior tyrosine...
Melanoma Research Alliance Appoints Marc Hurlbert, PhD, as Chief Science Officer
The Melanoma Research Alliance (MRA) recently appointed Marc Hurlbert, PhD, as the organization’s Chief Science Officer. Dr. Hurlbert will succeed Louise Perkins, PhD, who will retire form the role after serving MRA for more than 5 years. As Chief Science Officer, Dr. Hurlbert will guide MRA’s...
FDA Approves Levoleucovorin for Treatment in Osteosarcoma, Colorectal Cancer
The U.S. Food and Drug Administration (FDA) recently approved levoleucovorin (Khapzory) injection, a folate analog, for three indications: rescue after high-dose methotrexate therapy in patients with osteosarcoma; diminishing the toxicity associated with overdosing on folic acid antagonists or...
Never a Doubt About a Career in Medicine for Anne S. Tsao, MD
There was no epiphany or family influences, as long as she can remember; Anne S. Tsao, MD, always wanted to be a doctor or, because of her love for caring for sick animals, a veterinarian. Dr. Tsao was born in Fountain Creek, Pennsylvania, but her parents moved to a suburb just outside of Chicago...
Cancer Care in the U.S. Prison System
A health-care system is evaluated by various metrics: one is how it cares for its most vulnerable patients. The United States spends far more on health care than any nation in the world, yet access to high-quality oncology services remains elusive to certain minority populations—none more so than...
Findings From the National Cancer Opinion Survey: Alternative Therapies, Cost of Care, and More
Nearly 4 in 10 Americans believe cancer can be cured solely through alternative therapies, according to ASCO's second annual National Cancer Opinion Survey. This is despite research showing that patients who use alternative therapies instead of standard cancer treatments have much higher...
Actively Recruiting Clinical Trials Focused on Immunotherapies for Lung Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on immunotherapies in lung cancer. These trials are studying combination therapies, radiotherapy plus immunotherapy, cancer vaccines, identifying biomarkers to immunotherapy...
The Antiseptic Era: 1876–1900
The text and photographs on this page are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photo below is from the volume titled “The Antiseptic Era: 1876–1900.” The photograph...
ASH Honors John E. Dick, PhD, and Reed E. Drews, MD, With 2018 Mentor Award
The American Society of Hematology (ASH) will recognize John E. Dick, PhD, of the University of Toronto, Princess Margaret Cancer Center, and Ontario Institute for Cancer Research in Toronto, and Reed E. Drews, MD, of Beth Israel Deaconess Medical Center in Boston, with the 2018 Mentor Award for...
ASH Honors Victor Hoffbrand, DM, FRCP, FMed Sci, With Lifetime Achievement Award
The American Society of Hematology (ASH) will recognize Victor Hoffbrand, DM, FRCP, FMed Sci, of the University College London, with the 2018 Wallace H. Coulter Award for Lifetime Achievement in Hematology, the Society’s highest honor. Dr. Hoffbrand will be recognized for his contributions to...
The Persephone Trial Reconsidered
Persephone is a 4,088-patient trial that Helena Margaret Earl, MBBS, PhD, reported at the 2018 ASCO Annual Meeting as establishing that 6 months of trastuzumab (Herceptin) is not inferior to 12 months in 4-year survival without invasive or local regional recurrence or distant metastases. Dr. Earl...
The Persephone Trial Reconsidered
The Persephone presentation by Helena Margaret Earl, MBBS, PhD, got a lot of publicity after a pre–ASCO Annual Meeting press release, suggesting that 6 months of adjuvant trastuzumab (Herceptin) is enough. The advice of experts has been that the evidence is inconclusive, but I have not heard a...
Health-Policy Forum Focuses on New Care-Delivery Paradigms
What was an MBA doing at the podium of a clinical oncology meeting? Ten years ago or so, that might have been surprising. But in an era of rapid change—in therapies, costs, payment models, and practice—it only makes sense. Amy Porter-Tacoronte, MBA, Health System Chief Administrative Officer at the ...
The COLORS Training: Online LGBT Cultural Competency for Oncologists
An interactive online LGBT cultural competency training program for oncologists may be acceptable and feasible—and may improve LGBT-related knowledge and clinical practices, according to preliminary results of a pilot study of oncologists in Florida presented by Schlumbrecht et al at...
Prognostic Risk Model for African American Women With Breast Cancer
A prognostic model developed using a machine learning approach may be able to identify African American patients with breast cancer who have an increased risk of death, according to results of a study presented by Bhattarai et al at the 11th AACR Conference on The Science of Cancer Health...
FDA Grants Breakthrough Therapy Designation to LOXO-292 for RET Fusion–Positive Thyroid Cancer
The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation to LOXO-292, a selective RET inhibitor, for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have had disease progression following...
ESMO 2018: CTONG 1103 Finds Benefit With Neoadjuvant Erlotinib in Some EGFR-Mutated NSCLCs
Neoadjuvant erlotinib (Tarceva) benefits selected patients with epidermal growth factor receptor (EGFR)-mutated non–small cell lung cancer (NSCLC) who undergo complete resection of stage IIIA-N2 disease, according to a randomized study comparing erlotinib with gemcitabine plus cisplatin as...
ESMO 2018: CheckMate-142 Reports New Data on First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-H/dMMR Metastatic Colorectal Cancer
The combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) could become a new first-line treatment in patients with microsatellite instability–high (MSI-H), mismatch repair–deficient (dMMR) metastatic colorectal cancer, following results from the CheckMate-142 trial reported ...
2018 ASTRO: Phase I Trial of SBRT for Oligometastatic Disease With Multiple Metastases
The phase I NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used safely in patients with oligometastatic disease characterized by multiple metastases. Results from the trial indicate that using SBRT is safe as treatment for patients with 2 ...
Fluoropyrimidine DPYD Genotype–Guided Dosing in Patients With Cancer
In a Dutch study reported in The Lancet Oncology, Henricks et al found that DPYD genotype–guided dosing reduced the frequency of severe fluoropyrimidine toxicity in patients with cancer. Increased fluoropyrimidine toxicity is associated with reduced activity of the metabolic...
Quality of Life With Postmastectomy Radiotherapy vs No Radiotherapy in Intermediate-Risk Breast Cancer
In a 2-year follow-up of the phase III SUPREMO trial reported in The Lancet Oncology, Velikova et al found worse chest wall symptoms in women with intermediate-risk breast cancer who did vs did not receive postmastectomy radiotherapy. No other differences in quality-of-life outcomes were found ...
New ASTRO/ASCO/AUA Guideline for Early-Stage Prostate Cancer Supports Use of Hypofractionated Radiotherapy
Three prominent medical societies have issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external-beam radiation therapy (EBRT). Adoption of the guideline could make treatment shorter and more convenient for many patients with prostate cancer....
FDA Approves Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Squamous NSCLC
On October 30, 2018, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with carboplatin and either paclitaxel or nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) as first-line treatment of metastatic squamous non–small cell lung...
ESMO 2018: HOBOE-2: Zoledronic Acid in Premenopausal Hormone Receptor–Positive Early Breast Cancer
Adjuvant treatment with zoledronic acid, plus hormonal therapy with the aromatase inhibitor letrozole, significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor–positive early breast cancer, according to results reported by Perrone et al...
2018 ASTRO: SPPORT Trial: ADT With or Without Pelvic Lymph Node Radiation in Prostate Cancer
The first report of a large international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates, extending radiation therapy to the pelvic lymph nodes combined with adding short-term androgen-deprivation therapy (ADT) to standard treatment...
Risk Factors for Higher-Grade Transformation in Marginal Zone Lymphoma
In a single-institution study reported in the Journal of Clinical Oncology, Alderuccio et al found that not achieving complete remission (CR) after initial treatment, elevated lactate dehydrogenase (LDH), and more than four nodal sites at marginal zone lymphoma diagnosis are predictive of...
2018 ASTRO: IROCK: Stereotactic Ablative Radiotherapy for RCC in Patients With One Kidney
Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those with two, according to an analysis of an international data set presented by Correa et al at the 60th Annual Meeting of the American Society for...
2018 ASTRO: SABR-COMET: Stereotactic Ablative Radiation Therapy for Oligometastatic Tumors
In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can increase survival in patients with oligometastatic tumors. These findings were presented by Palma et al in the plenary session at the 60th Annual ...
IASLC Issues Statement on Lung Cancer Screening With Low-Dose Computed Tomography
The International Association for the Study of Lung Cancer (IASLC) recently issued a statement on lung cancer screening with low-dose computed tomography (CT) based on the results of the Dutch-Belgian NELSON lung cancer screening trial presented at the IASLC 19th World Conference on Lung Cancer...
2018 ASTRO: Overall Survival With Local Consolidative Therapy in Oligometastatic NSCLC
Adding radiation therapy or surgery to systemic therapy for patients with stage IV lung cancer whose cancer has spread to a limited number of sites can significantly extend overall survival, according to new results from a multicenter, randomized, controlled phase II study. The findings were...
2018 ASTRO: Liquid Biopsy in HPV-Associated Oral Cancer Surveillance
A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings were presented by...
2018 ASTRO: Radiation After Breast-Conserving Surgery in 'Good-Risk' DCIS
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery, but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report. These 12-year follow-up data from the only prospective,...
2018 ASTRO: FAST Trial Finds Long-Term Side Effects Similar for Once-Weekly and Conventional Breast Radiation Therapies
In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer, larger individual radiation doses experienced similarly low rates of late-onset side effects as those undergoing conventional radiation therapy. Findings from the...
2018 ASTRO: Combined Radiation and Cisplatin in HPV-Related Head and Neck Cancer
A phase III trial has determined that cisplatin chemotherapy combined with radiation therapy showed high amounts of activity in human papillomavirus (HPV)-related head and neck cancer. Findings from NRG-RTOG 1016 were presented by Trotti et al the 60th Annual Meeting of the American Society for...
2018 ASTRO: Radiation Therapy Outcomes in African American Patients With Prostate Cancer
A new analysis of genetic data from a large prospective registry and clinical data from several randomized trials indicates that African American patients may have comparatively higher cure rates when treated with radiation therapy than Caucasian patients. The study, which is the first report...
FDA Approves Levoleucovorin for Treatment in Osteosarcoma, Colorectal Cancer
The U.S. Food and Drug Administration (FDA) recently approved levoleucovorin (Khapzory) injection, a folate analog, for three indications: rescue after high-dose methotrexate therapy in patients with osteosarcoma; diminishing the toxicity associated with overdosage of folic acid...
Analysis of Prognostic Value of Postinduction PET Response After First-Line Immunochemotherapy for Follicular Lymphoma
In an analysis of the phase III GALLIUM trial reported in The Lancet Oncology, Trotman et al found that end-of-induction fluorodeoxyglucose positron-emission tomography (PET) after first-line immunochemotherapy appeared to better predict treatment outcomes than contrast-enhanced computed tomography ...
ESMO 2018: First-Line Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Pembrolizumab (Keytruda) improved survival in patients with head and neck cancer that has recurred or metastasized in the KEYNOTE-048 trial, according to late-breaking results from the study reported by Burtness et al at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract...
ESMO 2018: Cetuximab vs Cisplatin in Patients With HPV-Positive Oropharyngeal Cancer Receiving Radiotherapy
Patients with human papillomavirus (HPV)-positive throat cancer responded better to chemoradiotherapy than to cetuximab (Erbitux) with radiotherapy, according to late-breaking research reported by Mehanna et al at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract LBA9_PR)....
Philip J. DiSaia, MD, Former President, Society of Gynecologic Oncology, American Board of Obstetrics & Gynecology, Dies at 81
The grandson of Italian immigrants, Philip J. DiSaia was born on August 14, 1937, in Providence, Rhode Island. He earned his Bachelor’s in Science at Brown University and his MD at Tufts University. Upon the advice of his mentor in medical school, Dr. DiSaia obtained 2 years of general surgery...
Meta-analysis of Patients With Early Kidney Cancer Treated With Robotic Partial Nephrectomy
For patients with early kidney cancer, surgically removing a portion of the kidney instead of the whole organ is often a preferred treatment, because the procedure can effectively remove tumors while preserving kidney function. But when it comes to the best surgical approach—robotic, laparoscopic, ...
Sunitinib vs Nephrectomy Followed by Sunitinib in Metastatic Renal Cell Carcinoma
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, and colleagues found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by...
